利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

11 条记录 (耗时 0.018 秒)

    Methods of treating or preventing weight gain, obesity, and related disorders
    1.
    发明申请
    Methods of treating or preventing weight gain, obesity, and related disorders 有权
    治疗或预防体重增加，肥胖和相关疾病的方法

    公开(公告)号：US20020188029A1

    公开(公告)日：2002-12-12

    申请号：US10000806

    申请日：2001-12-04

    申请人： Sepracor Inc.

    发明人： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

    IPC分类号： A61K031/137

    CPC分类号： A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutramine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

    摘要翻译： 公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。 还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物及其药学上可接受的盐，溶剂化物和包合物。 优选的额外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT 3拮抗剂。

    Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same
    2.
    发明申请
    Derivatives of (-)- and (+)-venlafaxine and methods of preparing and using the same 审中-公开
    （ - ） - 和（+） - 文拉法辛的衍生物及其制备和使用方法

    公开(公告)号：US20040180952A1

    公开(公告)日：2004-09-16

    申请号：US10806423

    申请日：2004-03-23

    申请人： Sepracor Inc.

    发明人： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Nandkumar N. Bhongle

    IPC分类号： A61K031/277

    CPC分类号： C07C217/74 ,  A61K31/137 ,  A61K31/277 ,  C07B2200/07 ,  C07C213/00 ,  C07C213/02 ,  C07C215/64 ,  C07C2601/14

    摘要： Methods of preparing, and compositions comprising, derivatives of (null)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

    摘要翻译： 公开了制备方法和包含（ - ） - 文拉法辛的衍生物的组合物。 还公开了治疗和预防疾病和病症的方法，包括但不限于情感障碍如抑郁，双相和躁狂症，注意力缺陷障碍，具有多动症的注意缺陷障碍，帕金森病，癫痫，脑功能障碍，肥胖症和 体重增加，失禁，痴呆和相关疾病。

    Methods of treating or preventing erectile dysfunction
    3.
    发明申请
    Methods of treating or preventing erectile dysfunction 失效
    治疗或预防勃起功能障碍的方法

    公开(公告)号：US20030195261A1

    公开(公告)日：2003-10-16

    申请号：US10395298

    申请日：2003-03-25

    申请人： Sepracor Inc.

    发明人： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

    IPC分类号： A61K031/137

    CPC分类号： A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, and incontinence. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optically pure sibutrarnine metabolites and pharmaceutically acceptable salts, solvates, and clathrates thereof. Preferred additional pharmacologically active compounds include drugs that affect the central nervous system, such as 5-HT3 antagonists.

    摘要翻译： 公开了用于治疗和预防疾病和病症的方法，包括但不限于勃起功能障碍，情感障碍，体重增加，脑功能障碍，疼痛，强迫症，药物滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 所述方法包括施用多巴胺再摄取抑制剂和任选的另外的药理活性化合物。 还公开了包含多巴胺再摄取抑制剂和任选的另外的药理学活性化合物的药物组合物和剂型。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布睾胺代谢物及其药学上可接受的盐，溶剂化物和包合物。 优选的另外的药理活性化合物包括影响中枢神经系统的药物，例如5-HT <3> 拮抗剂。

    Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
    6.
    发明申请
    Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors 有权
    包含西布曲明代谢物与磷酸二酯酶抑制剂组合的组合物

    公开(公告)号：US20030096792A1

    公开(公告)日：2003-05-22

    申请号：US10278097

    申请日：2002-10-23

    申请人： Sepracor, Inc.

    发明人： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Qun K. Fang

    IPC分类号： A61K031/519 ,  A61K031/40 ,  A61K031/137

    CPC分类号： A61K31/50 ,  A61K9/2054 ,  A61K9/2059 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K31/40 ,  A61K31/415 ,  A61K31/44 ,  A61K31/475 ,  A61K31/495 ,  A61K31/505 ,  A61K31/52 ,  A61K45/06 ,  A61K2300/00

    摘要： Methods are disclosed for the treatment and prevention of disorders and conditions such as, but are not limited to: eating disorders; weight gain; obesity; irritable bowel syndrome; obsessive-compulsive disorders; platelet adhesion; apnea; affective disorders such as attention deficit disorders, depression, and anxiety; male and female sexual function disorders; restless leg syndrome; osteoarthritis; substance abuse including nicotine and cocaine addiction; narcolepsy; pain such as neuropathic pain, diabetic neuropathy, and chronic pain; migraines; cerebral function disorders; chronic disorders such as premenstrual syndrome; and incontinence. Pharmaceutical compositions and dosage forms are also disclosed which comprise a racemic or optically pure sibutramine metabolite and an optional additional pharmacologically active compound.

    摘要翻译： 公开了用于治疗和预防疾病和病症的方法，例如但不限于：进食障碍; 体重增加; 肥胖; 过敏性肠综合征; 强迫症; 血小板粘附; 呼吸暂停 情感障碍，如注意力缺陷障碍，抑郁症和焦虑症; 男性和女性性功能障碍; 不安腿综合征 骨关节炎 药物滥用，包括尼古丁和可卡因成瘾; 发作性睡病 疼痛如神经性疼痛，糖尿病性神经病和慢性疼痛; 偏头痛 脑功能障碍; 慢性疾病如经前期综合征; 和失禁。 还公开了药物组合物和剂型，其包含外消旋或光学纯的西布曲明代谢物和任选的另外的药理活性化合物。

    Methods of making N-desmethylzopiclone
    9.
    发明申请
    Methods of making N-desmethylzopiclone 审中-公开
    制备N-去甲基异佐匹克隆的方法

    公开(公告)号：US20030119841A1

    公开(公告)日：2003-06-26

    申请号：US10259851

    申请日：2002-09-30

    申请人： Sepracor, Inc.

    发明人： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Paul D. Rubin ,  Yaping Hong ,  Roger A. Bakale ,  Tingjian Xiang ,  Fran A. McConville

    IPC分类号： A61K031/498

    CPC分类号： A61K31/4985 ,  A61K31/498 ,  C07B2200/07 ,  C07D487/04

    摘要： The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (null)-N-desmethylzopiclone, and optically pure (null)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (null)-N-desmethylzopiclone, and optically pure (null)-N-desmethylzopiclone.

    摘要翻译： 本发明涉及包含外消旋的N-去甲基佐氮克隆，光学纯的（+） - N-去甲基佐匹克隆和光学纯的（ - ） - N-去甲基佐匹克隆的组合物，其用于治疗和预防哺乳动物的疾病和病症。 本发明进一步涉及制备N-去甲基异佐匹克隆，光学纯的（+） - N-去甲基佐匹克隆和光学纯的（ - ） - N-去甲基异佐匹克隆的新方法。

    Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine
    10.
    发明申请
    Methods of treating and preventing pain, anxiety, and incontinence using derivatives of (-)-venlafaxine 有权
    使用（ - ） - 文拉法辛的衍生物治疗和预防疼痛，焦虑和失禁的方法

    公开(公告)号：US20030018083A1

    公开(公告)日：2003-01-23

    申请号：US10222815

    申请日：2002-08-19

    申请人： Sepracor, Inc.

    发明人： Thomas P. Jerussi ,  Chrisantha H. Senanayake ,  Nandkumar N. Bhongle

    IPC分类号： A61K031/137

    CPC分类号： C07C217/74 ,  A61K31/137 ,  A61K31/277 ,  C07B2200/07 ,  C07C213/00 ,  C07C213/02 ,  C07C215/64 ,  C07C2601/14

    摘要： Methods of preparing, and compositions comprising, derivatives of (null)-venlafaxine are disclosed. Also disclosed are methods of treating and preventing diseases and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

    摘要翻译： 公开了制备方法和包含（ - ） - 文拉法辛的衍生物的组合物。 还公开了治疗和预防疾病和病症的方法，包括但不限于情感障碍如抑郁，双相和躁狂症，注意力缺陷障碍，具有多动症的注意缺陷障碍，帕金森病，癫痫，脑功能障碍，肥胖症和 体重增加，失禁，痴呆和相关疾病。